K Mohnike1,2, K Neumann3, P Hass4, M Seidensticker3, R Seidensticker3, M Pech3, S Klose5, T Streitparth3, B Garlipp6, C Benckert6, J J Wendler7, U B Liehr7, M Schostak7, D Göppner8, G Gademann4, J Ricke3. 1. Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany. konrad.mohnike@berlin-dtz.de. 2. DTZ am Frankfurter Tor, Kadiner Str.23, 10243, Berlin, Germany. konrad.mohnike@berlin-dtz.de. 3. Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany. 4. Klinik für Strahlentherapie, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany. 5. Klinik für Nieren- und Hochdruckkrankheiten, Diabetologie und Endokrinologie, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany. 6. Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany. 7. Klinik für Urologie und Kinderurologie, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany. 8. Klinik für Dermatologie, Universitätsklinikum Magdeburg A.ö.R., Otto-von-Guericke-Universität, Leipziger Straße 44, 39120, Magdeburg, Germany.
Abstract
PURPOSE: To assess the efficacy, safety, and outcome of image-guided high-dose-rate (HDR) brachytherapy in patients with adrenal gland metastases (AGM). MATERIALS AND METHODS: From January 2007 to April 2014, 37 patients (7 female, 30 male; mean age 66.8 years, range 41.5-82.5 years) with AGM from different primary tumors were treated with CT-guided HDR interstitial brachytherapy (iBT). Primary endpoint was local tumor control (LTC). Secondary endpoints were time to untreatable progression (TTUP), time to progression (TTP), overall survival (OS), and safety. In a secondary analysis, risk factors with an influence on survival were identified. RESULTS: The median biological equivalent dose (BED) was 37.4 Gy. Mean LTC after 12 months was 88%; after 24 months this was 74%. According to CTCAE criteria, one grade 3 adverse event occurred. Median OS after first diagnosis of AGM was 18.3 months. Median OS, TTUP, and TTP after iBT treatment were 11.4, 6.6, and 3.5 months, respectively. Uni- and multivariate Cox regression analyses revealed significant influences of synchronous disease, tumor diameter, and the total number of lesions on OS or TTUP or both. CONCLUSION: Image-guided HDR-iBT is safe and effective. Treatment- and primary tumor-independent features influenced survival of patients with AGM after HDR-iBR treatment.
PURPOSE: To assess the efficacy, safety, and outcome of image-guided high-dose-rate (HDR) brachytherapy in patients with adrenal gland metastases (AGM). MATERIALS AND METHODS: From January 2007 to April 2014, 37 patients (7 female, 30 male; mean age 66.8 years, range 41.5-82.5 years) with AGM from different primary tumors were treated with CT-guided HDR interstitial brachytherapy (iBT). Primary endpoint was local tumor control (LTC). Secondary endpoints were time to untreatable progression (TTUP), time to progression (TTP), overall survival (OS), and safety. In a secondary analysis, risk factors with an influence on survival were identified. RESULTS: The median biological equivalent dose (BED) was 37.4 Gy. Mean LTC after 12 months was 88%; after 24 months this was 74%. According to CTCAE criteria, one grade 3 adverse event occurred. Median OS after first diagnosis of AGM was 18.3 months. Median OS, TTUP, and TTP after iBT treatment were 11.4, 6.6, and 3.5 months, respectively. Uni- and multivariate Cox regression analyses revealed significant influences of synchronous disease, tumor diameter, and the total number of lesions on OS or TTUP or both. CONCLUSION: Image-guided HDR-iBT is safe and effective. Treatment- and primary tumor-independent features influenced survival of patients with AGM after HDR-iBR treatment.
Authors: Konrad Mohnike; Steffen Wolf; Robert Damm; Max Seidensticker; Ricarda Seidensticker; Frank Fischbach; Nils Peters; Peter Hass; Günther Gademann; Maciej Pech; Jens Ricke Journal: Strahlenther Onkol Date: 2016-02-29 Impact factor: 3.621
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: Jens Ricke; Peter Wust; Gero Wieners; Alexander Beck; Chie Hee Cho; Max Seidensticker; Maciej Pech; Michael Werk; Christian Rosner; Enrique Lopez Hänninen; Torsten Freund; Roland Felix Journal: J Vasc Interv Radiol Date: 2004-11 Impact factor: 3.464
Authors: Kamran A Ahmed; Brandon M Barney; O Kenneth Macdonald; Robert C Miller; Yolanda I Garces; Nadia N Laack; Michael G Haddock; Robert L Foote; Kenneth R Olivier Journal: Am J Clin Oncol Date: 2013-10 Impact factor: 2.339
Authors: Michael T Milano; Alan W Katz; Ann G Muhs; Abraham Philip; Daniel J Buchholz; Michael C Schell; Paul Okunieff Journal: Cancer Date: 2008-02-01 Impact factor: 6.860
Authors: G Carrafiello; D Laganà; C Recaldini; A Giorgianni; A Ianniello; D Lumia; A D'Ambrosio; M Petullà; G Dionigi; C Fugazzola Journal: Cardiovasc Intervent Radiol Date: 2008-04-18 Impact factor: 2.740
Authors: R Damm; T Streitparth; P Hass; M Seidensticker; C Heinze; M Powerski; J J Wendler; U B Liehr; K Mohnike; M Pech; J Ricke Journal: Strahlenther Onkol Date: 2019-07-25 Impact factor: 3.621